QuidelOrtho Reports Significant Q1 Loss and Revenue Decline, Announces $100M Acquisition
QDEL is trading near its 52-week low of $10.86 (6.4% above the low).
Summary
QuidelOrtho reported a significant Q1 2026 net loss and revenue decline, alongside a shift to negative operating cash flow, while also announcing a $100 million acquisition of LEX Diagnostics.
Key Events · Earnings and Guidance · QDEL
-
Significant Revenue Decline
Total revenues decreased by 11% to $619.8 million in Q1 2026, down from $692.8 million in Q1 2025, primarily due to lower respiratory product sales and the termination of a joint business arrangement.
-
Shift to Operating Loss
The company reported an operating loss of $31.8 million in Q1 2026, a significant reversal from the operating income of $32.6 million in Q1 2025.
-
Widened Net Loss
Net loss increased substantially to $91.8 million (EPS $(1.35)) in Q1 2026, compared to a net loss of $12.7 million (EPS $(0.19)) in the prior year period.
-
Negative Operating Cash Flow
Cash flow from operating activities turned negative, with $33.0 million used in Q1 2026, a sharp contrast to $65.6 million provided in Q1 2025.
Analysis · QDEL · Life Sciences
QuidelOrtho's Q1 2026 results detail a substantial financial downturn, confirming the preliminary announcement from the recent 8-K. The company experienced a significant revenue decrease, a shift from operating income to a considerable operating loss, and a widened net loss. This financial deterioration is compounded by negative operating cash flow. Concurrently, the company disclosed a material acquisition of LEX Diagnostics for $100 million, funded by new debt, which represents a significant capital allocation during a challenging period. Investors should note the immediate financial headwinds alongside the strategic investment in molecular diagnostics.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QDEL was trading at $11.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $793.8M. The 52-week trading range was $10.86 to $38.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.